Teva Pharmaceutical Industries Ltd. (TEVA)

Teva Pharmaceutical Industries Ltd. is trading near the top of its 52-week range, at $42.40 and 2.17% below its 52-week high of $43.34. The stock has risen 74.77% over the past year, and it sits 6.64% above its 50-day average and 21.35% above its 200-day average. Analysts remain positive, with 13 of 15 rating it Buy and a median 12-month target of $48.50.

Recent analyst activity has been uniformly supportive. Leerink Partners kept its Outperform rating on November 5, 2026. TD Cowen and HC Wainwright & Co. each kept their Buy ratings on November 4, 2026, and HC Wainwright started coverage at Buy on November 2, 2026. Barclays kept its Overweight rating on October 15, 2026, and JP Morgan did the same on October 12, 2026. Of the 15 analysts with a current rating, 13 rate the stock Buy and 2 rate it Hold, with none at Sell. Three months ago the count was 12 Buy out of 12 total ratings, so the consensus has not weakened, though the number of ratings has risen.

The trailing P/E of 98.60 is at a premium to peers and sits 209.1% above the sector median of 31.9. The price-to-sales ratio of 2.87 is 15.6% below the sector median of 3.4, so the premium is tied to earnings rather than sales. Trailing GAAP earnings per share are $0.43, which is a thin base for the price. Analysts expect EPS of $2.06 this year and $3.12 next year, so the valuation depends on those estimates being met.

The net profit margin is 2.94% and return on equity is 6.65%, below the sector median of 7.3%. Debt-to-equity is 2.13. The operating margin of 27.40% is far higher than the net margin, which points to heavy costs below the operating line. The company pays no dividend, so returns to shareholders depend entirely on the share price.

Insiders sold $76.1M of stock over the last 18 months across 26 sales, while one open-market purchase totaling $21K was recorded. Insider sales are often planned in advance or made to cover tax on vesting shares, so the sales carry less signal than the purchase, which is small.

The base case is that the stock keeps its upward trend while it stays above its 50-day and 200-day moving averages ($39.76 and $34.94), with the price moving within its typical daily swing of 1.66%. Analyst support is the main reason for the constructive view: the median target of $48.50 sits 14.4% above the price, and the highest target is $57.00. The stock would be better supported if quarterly revenue returns to growth, since analysts expect revenue to shrink 2.8% this year but EPS to grow 51.2% next year to $3.12. The case weakens if the price closes below the 20-day EMA and 50-day SMA, which would signal that the rally is losing ground, or if the lowest target of $42.00, which is close to the current price, begins to look like a ceiling. Earnings are the key test, because at a P/E of 98.60 the valuation leaves little room for disappointment.

Support sits first at the 20-day EMA of $41.29, which the price has been holding above. Below that is the 50-day SMA at $39.76, which is the next level a fall would meet. The 200-day SMA at $34.94 is the deeper support, and the 52-week low of $24.01 marks the bottom of the range. Resistance is the 52-week high at $43.34, the first level a rise would meet. Beyond that, the analysts' lowest target of $42.00 and median target of $48.50 serve as the forecast markers above the price.